Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Raltegravir - Merck & Co

Drug Profile

Raltegravir - Merck & Co

Alternative Names: Isentress; ISENTRESS HD; L 900612; MK-0518; RAL

Latest Information Update: 30 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Developer Merck & Co; National Institute of Allergy and Infectious Diseases; The French National Agency for Research on AIDS and Viral Hepatitis
  • Class Antiretrovirals; Naphthyridines; Organic chemicals; Small molecules
  • Mechanism of Action HIV integrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV-1 infections
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 28 Nov 2018 The French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis, in collaboration with Merck completes a phase-III clinical trial in HIV-1 infections (Combination therapy, Treatment-naive) in Brazil, France, Ivory Coast, Mozambique and Vietnam (PO) in November 2018(NCT02273765)
  • 07 Sep 2018 Intellectual Property High Court of Japan dismisses Shionogi’s lawsuit filed against MSD in Japan
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top